Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

Bausch + Lomb Introduces Biotrue® ONEday for Astigmatism Contact Lenses

New Innovative Daily Disposable Lens Designed to Provide Astigmatic Patients Consistently Clear Vision and Comfort Throughout the Day



BRIDGEWATER, NJ – Bausch + Lomb, a leading global eye health company, today announced the introduction of Biotrue® ONEday for Astigmatism daily disposable contact lenses. Approximately 73.2 million people in the U.S. are astigmatic, but only 8.8 million people are currently wearing toric contact lenses. Biotrue® ONEday for Astigmatism helps eye care practitioners capture this astigmatic opportunity by offering patients the convenience of a daily disposable contact lens with the innovation of an evolved peri-ballast design for stability and Surface Active Technology™ to help the lens maintain 98% of its moisture for up to 16 hours1.

“We are excited to complete the Biotrue® ONEday family of lenses with the addition of Biotrue® ONEday for Astigmatism,” said Guy Guglielmino, vice president of marketing, U.S. Vision Care, Bausch + Lomb. “Innovations in contact lens materials and design allow us to meet the challenging demands of today’s astigmatic patients.”


Similar to Biotrue® ONEday and Biotrue® ONEday for Presbyopia, Biotrue® ONEday for Astigmatism utilizes Surface Active TechnologyTM. This technology uses a large volume of hydrophilic polyvinylpyrrilidone (PVP), a water loving molecule, and Poloxamer 407, a surface active macromer, to form a unique dehydration barrier that helps the lens maintain 98% of its moisture for up to 16 hours1.


As part of the development process, Bausch + Lomb evaluated various ballasting mechanisms and assessed dynamics of blink patterns across a wide range of patients using high speed videography. To achieve the combination that performed the best in the high-water content material of Biotrue® ONEday contact lenses, engineers created an evolved peri-ballast design that employs spherical aberration control in both axes to help reduce halos and glare, even in low-light conditions2.


“Approximately 42 percent of vision corrected teens and adults in the United States have been diagnosed with astigmatism3 and it is often a challenge to fit them with a lens that has the right combination of visual clarity and comfort to meet their unique vision correction needs,” said Mile Brujic, O.D., partner of Premier Vision Group in Bowling Green, OH. “I’m delighted to be able to now offer my astigmatic patients the comfort and clarity2 they need in the convenient form of a daily disposable lens.”


For more information on the Biotrue® ONEday for Astigmatism contact lenses, please visit:

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people’s eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries.


  1. Data on file. Bausch & Lomb Incorporated. Rochester, NY; 2012.
  2. Results from a 7-investigator, multi-site study of Biotrue® ONEday for Astigmatism contact lenses on 123 current non-daily disposable toric soft contact lens wearers. Lenses were worn on a daily wear basis for 1 week.
  3. The Multi-Sponsor Survey’s Inc. 2016 Gallup Target Report on the Market for Toric Contact Lenses. August 2016.


®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.
© 2017 Bausch & Lomb Incorporated.


News Media Contacts:

Kristy Marks
Sr. Manager, Communications, Bausch + Lomb

(908) 927-0683 or


Don Murphy

Zeno Group, on behalf of Bausch + Lomb

(212) 299-8970 or



Actions: E-mail | Permalink |